Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide

José L. McFaline-Figueroa, Christian J. Braun, Monica Stanciu, Zachary D. Nagel, Patrizia Mazzucato, Dewakar Sangaraju, Edvinas Cerniauskas, Kelly Barford, Amanda Vargas, Yimin Chen, Natalia Tretyakova, Jacqueline A. Lees, Michael T. Hemann, Forest M. White, Leona D. Samson

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment. Here, we report that in GBM cells, even a modest decrease in the mismatch repair (MMR) components MSH2 and MSH6 have profound effects on temozolomide sensitivity. RNAi-mediated attenuation of MSH2 and MSH6 showed that such modest decreases provided an unexpectedly strong mechanism of temozolomide resistance. In a mouse xenograft model of human GBM, small changes in MSH2 were sufficient to suppress temozolomide-induced tumor regression. Using The Cancer Genome Atlas to analyze mRNA expression patterns in tumors from temozolomide-treated GBM patients, we found that MSH2 transcripts in primary GBM could predict patient responses to initial temozolomide therapy. In recurrent disease, the absence of microsatellite instability (the standard marker for MMR deficiency) suggests a lack of involvement of MMR in the resistant phenotype of recurrent disease. However, more recent studies reveal that decreased MMR protein levels occur often in recurrent GBM. In accordance with our findings, these reported decreases may constitute a mechanism by which GBM evades temozolomide sensitivity while maintaining microsatellite stability. Overall, our results highlight the powerful effects of MSH2 attenuation as a potent mediator of temozolomide resistance and argue that MMR activity offers a predictive marker for initial therapeutic response to temozolomide treatment.

Original languageEnglish (US)
Pages (from-to)3127-3138
Number of pages12
JournalCancer Research
Volume75
Issue number15
DOIs
StatePublished - Aug 1 2015

Fingerprint Dive into the research topics of 'Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide'. Together they form a unique fingerprint.

Cite this